Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Marie Young

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
The Lancet. Oncology|November 4, 2004
Cardiotoxicity after liposomal anthracyclinesAnne Marie Young, Tony Dhillon, Mark Bower
Expert Opinion on Investigational Drugs|December 1, 2010
Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatinAdam J Foley-Comer, Anne-Marie Young, Fiona Russell-Yarde, et al.
Journal of Cardiovascular Pharmacology|July 24, 2012
Evidence of a drug-drug interaction linked to inhibition of ester hydrolysis by orlistatDarren Bentley, Anne-Marie Young, Lucy Rowell, et al.
Expert Opinion on Investigational Drugs|August 27, 2010
No clinically relevant drug-drug interactions when dalcetrapib is co-administered with atorvastatinMichael Derks, Markus Abt, Graeme Parr, et al.
International Journal of Cancer|March 10, 2005
Hepatitis C infection is not associated with systemic HIV-associated non-Hodgkin's lymphoma: a cohort studyLaura Waters, Justin Stebbing, Sundhiya Mandalia, et al.
Investigational New Drugs|February 6, 2020
Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemiaGeoffrey L Uy, Sarit Assouline, Anne-Marie Young, et al.
Blood|July 9, 2004
Protease inhibitors potentiate chemotherapy-induced neutropeniaMark Bower, Neil McCall-Peat, Natalie Ryan, et al.
Investigational New Drugs|November 18, 2019
A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumorsAlbiruni R Abdul Razak, Wilson H Miller, Geoffrey L Uy, et al.
Annals of Internal Medicine|August 17, 2005
A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapyMark Bower, Brian Gazzard, Sundhiya Mandalia, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The Lancet. Oncology|November 4, 2004
Cardiotoxicity after liposomal anthracyclinesAnne Marie Young, Tony Dhillon, Mark Bower
Expert Opinion on Investigational Drugs|December 1, 2010
Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatinAdam J Foley-Comer, Anne-Marie Young, Fiona Russell-Yarde, et al.
Journal of Cardiovascular Pharmacology|July 24, 2012
Evidence of a drug-drug interaction linked to inhibition of ester hydrolysis by orlistatDarren Bentley, Anne-Marie Young, Lucy Rowell, et al.
Expert Opinion on Investigational Drugs|August 27, 2010
No clinically relevant drug-drug interactions when dalcetrapib is co-administered with atorvastatinMichael Derks, Markus Abt, Graeme Parr, et al.
International Journal of Cancer|March 10, 2005
Hepatitis C infection is not associated with systemic HIV-associated non-Hodgkin's lymphoma: a cohort studyLaura Waters, Justin Stebbing, Sundhiya Mandalia, et al.
Investigational New Drugs|February 6, 2020
Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemiaGeoffrey L Uy, Sarit Assouline, Anne-Marie Young, et al.
Blood|July 9, 2004
Protease inhibitors potentiate chemotherapy-induced neutropeniaMark Bower, Neil McCall-Peat, Natalie Ryan, et al.
Investigational New Drugs|November 18, 2019
A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumorsAlbiruni R Abdul Razak, Wilson H Miller, Geoffrey L Uy, et al.
Annals of Internal Medicine|August 17, 2005
A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapyMark Bower, Brian Gazzard, Sundhiya Mandalia, et al.
Pageof 1